StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a research note released on Friday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Separately, Roth Mkm reduced their price objective on shares of Aptevo Therapeutics from $15.00 to $8.00 and set a buy rating on the stock in a research note on Monday, September 23rd.
Read Our Latest Research Report on APVO
Aptevo Therapeutics Stock Down 0.4 %
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share for the quarter, topping the consensus estimate of ($1.93) by $0.26. As a group, sell-side analysts forecast that Aptevo Therapeutics will post -4.3 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Aptevo Therapeutics
An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC bought a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 8.06% of the company’s stock.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Read More
- Five stocks we like better than Aptevo Therapeutics
- Following Congress Stock Trades
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- Best Stocks Under $10.00
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Golden Cross Stocks: Pattern, Examples and Charts
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.